Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model

@article{Kletting2010RadioimmunotherapyWA,
  title={Radioimmunotherapy with Anti-CD66 Antibody: Improving the Biodistribution Using a Physiologically Based Pharmacokinetic Model},
  author={P. Kletting and T. Kull and D. Bunjes and Bettina Mahren and M. Luster and S. Reske and G. Glatting},
  journal={Journal of Nuclear Medicine},
  year={2010},
  volume={51},
  pages={484 - 491}
}
To improve radioimmunotherapy with anti-CD66 antibody, a physiologically based pharmacokinetic (PBPK) model was developed that was capable of describing the biodistribution and extrapolating between different doses of anti-CD66 antibody. Methods: The biodistribution of the 111In-labeled anti-CD66 antibody of 8 patients with acute leukemia was measured. The data were fitted to 2 PBPK models. Model A incorporated effective values for antibody binding, and model B explicitly described mono- and… Expand
Dependence of the anti-CD66 antibody biodistribution on the dissociation constant: a simulation study.
TLDR
The simulations indicate that a considerably increased therapeutic index can be obtained by decreasing the dissociation constant, and new anti-CD66 antibodies with lower dissociation constants should be developed. Expand
Optimal preloading in radioimmunotherapy with anti-cD45 antibody.
TLDR
The presented method can be used to individually determine the optimal preload and the corresponding residence times in radioimmunotherapy with anti-CD45 antibody. Expand
Physiologically Based Pharmacokinetic Modeling Is Essential in 90Y-Labeled Anti-CD66 Radioimmunotherapy
TLDR
Individual treatment is needed due to biological differences between patients in RIT with 90Y-labeled anti-CD66 antibody because of differences in pre-therapeutic and therapeutic biokinetics, which could be predicted using the PBPK models. Expand
Analysing saturable antibody binding based on serum data and pharmacokinetic modelling.
TLDR
Using the presented method, relevant saturable binding for radioimmunotherapy with (90)Y-labelled anti-CD66 antibody is identified solely based on serum data and may also be applicable to investigate other systems where saturation of binding sites might be important. Expand
Potential of optimal preloading in anti-CD20 antibody radioimmunotherapy: an investigation based on pharmacokinetic modeling.
TLDR
A pharmacokinetic model that describes the biodistribution of anti-CD20 antibody was developed and the optimal amount of unlabeled antibody was determined, which indicates that a personalized approach for radioimmunotherapy (RIT) with anti- CD20 antibody is required to account for the interpatient variability. Expand
A new pharmacokinetic model for 90Y-ibritumomab tiuxetan based on 3-dimensional dosimetry
TLDR
This model provides exchange constants between the different tissues, Area Under the Curve of 111In-IT in blood (AUC) and Mean Residence Time (MRT) that have not been reported so far for IT and suggests the metabolism of mAbs may take place mainly on the vascular compartment level. Expand
Physiologically based pharmacokinetic modeling of (18)F-SiFAlin-Asp3-PEG1-TATE in AR42J tumor bearing mice.
TLDR
Biokinetics of this tracer can be accurately and adequately described using a physiologically based pharmacokinetic model including receptor-mediated endocytosis, and an optimized translation from bench to bedside is possible. Expand
Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy.
TLDR
This study investigates if this assumption is justified in sst2-receptor targeting peptide therapy, as unequal amounts of peptide and different peptides for pretherapeutic measurements and therapy are commonly used. Expand
Important Pharmacokinetic Parameters for Individualization of 177 Lu-PSMA Therapy: A Global Sensitivity Analysis for a Physiologically-Based Pharmacokinetic Model.
TLDR
The results suggest that an accurate measurement of receptor density and flow before therapy could be a promising approach for developing an individualized treatment with 177 Lu-labeled PSMA-targeting radioligands. Expand
Utility of physiologically based pharmacokinetic (PBPK) modeling in oncology drug development and its accuracy: a systematic review
TLDR
PBPK modeling is a potential tool which can be effectively applied throughout all phases of oncology drug development, and the number of experimental animals and human participants enrolled in the studies can be reduced using P BPK modeling and PBPK-population-PK modeling. Expand
...
1
2
3
4
...

References

SHOWING 1-10 OF 44 REFERENCES
Improving Anti-CD45 Antibody Radioimmunotherapy Using a Physiologically Based Pharmacokinetic Model
TLDR
A physiologically based pharmacokinetic model is developed to individually determine the optimal preload for radioimmunotherapy with the YAML568 anti-CD45 antibody for each patient, finding a more selective delivery of radioactivity to the target organ and a reduction in the toxicity to normal tissue are achieved by determining the optimalPreload. Expand
Modelling radioimmunotherapy with anti-CD45 antibody to obtain a more favourable biodistribution.
TLDR
The developed model qualitatively describes how a preload can considerably increase selectivity of RIT due to different blood flows and antigen distribution in relevant organs. Expand
Anti-CD45 monoclonal antibody YAML568: A promising radioimmunoconjugate for targeted therapy of acute leukemia.
TLDR
This study shows that the anti-CD45 monoclonal antibody YAML568 is suitable for delivering selectively radiation to hematopoietic tissues when labeled with 90Y provided that a preloading dose of about 0.5 mg/kg unlabeled antibody is given. Expand
Radioimmunoconjugates in acute leukemia treatment: the future is radiant
Summary:Targeted radiotherapy of the bone marrow using radiolabeled monoclonal antibodies is a therapeutic approach of considerable potential for the treatment of acute leukemia in addition to or asExpand
Kinetic model for the biodistribution of an 111In-labeled monoclonal antibody in humans.
TLDR
The proposed nonlinear compartmental model predicts the dose levels required to overcome saturable background, suggests appropriate doses and schedules for cold loading strategies, and provides a format for explicit inclusion of tumor antigen. Expand
A Physiologically Based Pharmacokinetic Model of Docetaxel Disposition: from Mouse to Man
TLDR
The murine PBPK model developed can accurately predict plasma and tissue levels at the 5 and 20 mg/kg doses and is capable of estimating plasma levels at 30, 36, and 100 mg/m2. Expand
Effect of dose, molecular size, affinity, and protein binding on tumor uptake of antibody or ligand: a biomathematical model.
TLDR
A mathematical model has been developed to determine the best approach to improving tumor targeting with antibody and indicates that success requires an optimal combination of dose, size, and binding affinity of antibody. Expand
Use of antibodies and immunoconjugates for the therapy of more accessible cancers.
TLDR
A number of immunoconjugates are being examined in settings where the disease is more easily accessible, or within compartments that allow easier and more direct access to the tumor, or both locally and systemically, in adjuvant situations. Expand
A two-tiered physiologically based model for dually labeled single-chain Fv-Fc antibody fragments
TLDR
The construction of a two-tiered physiologically based pharmacokinetic model capable of simulating the apparent biodistribution of both 111In- and 125I-labeled scFv-Fc mAbs is described, which permits estimation of the degradation capacity of each organ and elucidates the dependence of cumulative degradation in liver, muscle, and skin on FcRn affinity and tumor mass. Expand
Similarities and differences in 111In- and 90Y-labeled 1B4M-DTPA antiTac monoclonal antibody distribution.
TLDR
It appears that 111In can be used as a surrogate marker for 90Y when labeling antiTac with the 1 B4M chelate, although underestimates of the bone marrow radiation dose should be anticipated. Expand
...
1
2
3
4
5
...